Cargando…

A longitudinal model for disease progression was developed and applied to multiple sclerosis

OBJECTIVES: To develop a model of disease progression using multiple sclerosis (MS) as an exemplar. STUDY DESIGN AND SETTINGS: Two observational cohorts, the University of Wales MS (UoWMS), UK (1976), and British Columbia MS (BCMS) database, Canada (1980), with longitudinal disability data [the Expa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawton, Michael, Tilling, Kate, Robertson, Neil, Tremlett, Helen, Zhu, Feng, Harding, Katharine, Oger, Joel, Ben-Shlomo, Yoav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643305/ https://www.ncbi.nlm.nih.gov/pubmed/26071892 http://dx.doi.org/10.1016/j.jclinepi.2015.05.003

Ejemplares similares

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

The effect of smoking on the symptoms and progression of multiple sclerosis: a review
por: Shirani, Afsaneh, et al.
Publicado: (2010)

New rare genetic variants in multiple sclerosis
por: Harding, Katharine E., et al.
Publicado: (2018)

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
por: Palace, Jacqueline, et al.
Publicado: (2014)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

A multiple sclerosis disease progression measure based on cumulative disability
por: Manouchehrinia, Ali, et al.
Publicado: (2021)

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
por: Shirani, Afsaneh, et al.
Publicado: (2015)

The Multiple Sclerosis Prodrome: Evidence to Action
por: Tremlett, Helen, et al.
Publicado: (2022)

Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review
por: McKay, Kyla A., et al.
Publicado: (2015)

Evidence for a two-stage disability progression in multiple sclerosis
por: Leray, Emmanuelle, et al.
Publicado: (2010)

Polypharmacy and multiple sclerosis: A population-based study
por: Chertcoff, Anibal, et al.
Publicado: (2022)

Accurate classification of secondary progression in multiple sclerosis using a decision tree
por: Ramanujam, Ryan, et al.
Publicado: (2020)

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study
por: Zhang, Tingting, et al.
Publicado: (2017)

The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients – No
por: Tremlett, Helen, et al.
Publicado: (2021)

Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children
por: Razaz, Neda, et al.
Publicado: (2016)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Associations of GP practice characteristics with the rate of ambulatory care sensitive conditions in people living with dementia in England: an ecological analysis of routine data
por: Eyles, Emily, et al.
Publicado: (2021)

Children and adolescents adjustment to parental multiple sclerosis: a systematic review
por: Razaz, Neda, et al.
Publicado: (2014)

Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course
por: Nourbakhsh, Bardia, et al.
Publicado: (2018)

Commentary: “Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: a systematic review and meta-analysis”
por: Lawton, Michael, et al.
Publicado: (2023)

Neonatal and Delivery Outcomes in Women with Multiple Sclerosis
por: van der Kop, Mia L, et al.
Publicado: (2011)

Challenges in examining area effects across the life course on physical capability in mid-life: Findings from the 1946 British Birth Cohort
por: Murray, Emily T., et al.
Publicado: (2012)

Area Deprivation Across the Life Course and Physical Capability in Midlife: Findings From the 1946 British Birth Cohort
por: Murray, Emily T., et al.
Publicado: (2013)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada
por: McKay, Kyla, et al.
Publicado: (2017)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Model Selection of the Effect of Binary Exposures over the Life Course
por: Smith, Andrew D. A. C., et al.
Publicado: (2015)

Longitudinal change in TSPO PET imaging in progressive multiple sclerosis
por: Kang, Yeona, et al.
Publicado: (2021)

Age Related Multiple Sclerosis Severity Score: Disability ranked by age
por: Manouchehrinia, Ali, et al.
Publicado: (2017)

Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2019)

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator
por: Boggild, Mike, et al.
Publicado: (2009)

Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity
por: Zhang, Tingting, et al.
Publicado: (2020)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Quality of relationships in mothers and their partners in the Avon Longitudinal Study of Parents and Children
por: Tohidinik, Hamid Reza, et al.
Publicado: (2023)

Interpretation of vaccine associated neurological adverse events: a methodological and historical review
por: Cauchi, Marija, et al.
Publicado: (2021)

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
por: Evans, Charity, et al.
Publicado: (2021)

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
por: Zhang, Tingting, et al.
Publicado: (2016)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ef8fb1gkq19l7uoghljsg6n7q1